论文部分内容阅读
目的观察紫杉醇联合顺铂方案新辅助化疗治疗进展期食管癌的临床疗效。方法将62例进展期食管癌患者随机分为研究组与对照组,各31例。2组患者均采用6MV-X射线照射行三维适形放疗,研究组予以紫杉醇联合顺铂方案新辅助化疗,对照组予以5-氟尿嘧啶联合顺铂方案新辅助化疗。对比2组患者临床效果、毒副反应发生情况及1、2年存活率。结果研究组患者的临床总有效率和1、2年存活率均高于对照组(P<0.05)。2组毒副反应发生情况比较差异无统计学意义(P>0.05)。结论紫杉醇联合顺铂方案新辅助化疗治疗进展期食管癌可显著提高患者的临床总有效率及远期生存率,且不增加其毒副反应,在临床治疗中具有重要价值。
Objective To observe the clinical efficacy of paclitaxel combined with cisplatin neoadjuvant chemotherapy in the treatment of advanced esophageal cancer. Methods Sixty-two patients with advanced esophageal cancer were randomly divided into study group and control group, with 31 cases in each group. Two groups of patients were treated with 3-dimensional conformal radiotherapy by 6MV-X-ray irradiation. The study group received neoadjuvant chemotherapy with paclitaxel plus cisplatin and the control group with neoadjuvant chemotherapy with 5-fluorouracil and cisplatin. The clinical effects, side effects and 1 and 2 year survival rates of two groups were compared. Results The total clinical effective rate and the 1 and 2 year survival rates in study group were higher than those in control group (P <0.05). There was no significant difference in the incidence of side effects between the two groups (P> 0.05). Conclusion Paclitaxel plus cisplatin regimen of neoadjuvant chemotherapy for advanced esophageal cancer can significantly improve the patient’s total clinical and long-term survival rate of survival, and does not increase its toxicity, in the clinical treatment of great value.